Every Form 4 that Roivant Sciences Ltd. (ROIV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ROIV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ROIV filings page.
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an exercise-and-sale transaction in the company’s common shares. He exercised stock options to acquire 200,000 common shares at $3.85 per share and sold 200,000 common shares in open-market transactions at a weighted average price of $29.59 per share, with individual trade prices ranging from $29.33 to $29.88. Following these transactions, he directly holds 1,647,546 common shares. A related stock option award to purchase common shares is described as fully vested.
Pulik Richard reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences CFO Richard Pulik received equity compensation on April 20, 2026. He was granted 60,644 Common Shares as restricted stock units and now holds 297,511 Common Shares directly. He also received 84,026 stock options to buy Common Shares at $29.08 per share, expiring in 2036.
The RSUs vest 25% one year after April 20, 2026, with the rest in twelve equal quarterly installments. The options vest 25% one year after that date, then in thirty-six equal monthly installments, all subject to his continued service.
Roivant Sciences Ltd. reported a compensation-related equity grant to Chief Accounting Officer Jennifer Humes. She received 29,173 Common Share RSUs, bringing her direct Common Share holdings to 113,364 shares after the award.
Humes was also granted 27,157 stock options to buy Common Shares at an exercise price of $29.08 per share, expiring on April 19, 2036. Both the RSUs and options have a vesting commencement date of April 20, 2026 and vest over time, subject to her continuous service with the company.
Roivant Sciences Ltd. director Oren Ilan reported compensation-related share movements. He received an award of 896 Common Shares under the company’s Non-Employee Director Compensation Plan, which was fully vested on the grant date. To cover tax withholding obligations on previously granted shares that vested and settled, 95 Common Shares were withheld and settled on a net basis by the company. Following these transactions, Ilan directly holds 120,229 Common Shares.
Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 670 Common Shares as equity compensation. The award was made under the company’s Non-Employee Director Compensation Plan and was fully vested on the grant date. Following this grant, she directly holds 16,474 Common Shares.
Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. He received 469 Common Shares as an award under Roivant’s Non-Employee Director Compensation Plan, which were fully vested on the grant date. To cover related tax withholding obligations, 94 previously granted Common Shares were net-settled back to the company. After these transactions, he directly holds 109,405 Common Shares. These entries reflect compensation and tax withholding mechanics rather than open-market buying or selling.
Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share. According to the filing, the trades occurred across multiple transactions between $28.98 and $29.36. After these sales, he directly owns 16,736,116 common shares.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported an open-market sale of 13,538 Common Shares of Roivant Sciences on April 8, 2026. The weighted average sale price was $28.37 per share, with individual trades executed between $28.36 and $28.38. After this transaction, she directly holds 84,191 Common Shares.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 160,035 common shares withheld on March 31, 2026 to cover tax obligations tied to previously granted RSUs. The issuer net settled these RSUs to satisfy applicable tax withholding, and Torti now directly holds 13,576,512 common shares.
Roivant Sciences CEO Matthew Gline exercised capped value appreciation rights and had shares withheld to cover taxes. On March 30, 2026, 2,178,150 vested CVARs were settled into 97,319 Common Shares, and a portion of these was net-settled to satisfy tax withholding obligations. On March 31, 2026, additional Common Shares from previously granted RSUs were also net-settled for tax withholding. After these compensation-related transactions, Gline directly held 17,025,890 Common Shares, indicating he retained a large equity position and that the dispositions were primarily for tax obligations rather than open-market trading.
Roivant Sciences Ltd. director and President & CIO Mayukh Sukhatme exercised equity awards and had shares withheld for taxes. On March 30, 2026, he exercised 1,306,889 Capped Value Appreciation Rights, which were settled into 58,391 Common Shares based on the closing share price that day.
The issuer then conducted net share settlements to cover tax obligations, withholding 29,809 Common Shares at $26.41 related to the CVAR settlement and 187,512 Common Shares at $27.70 tied to previously granted RSUs. After these non‑market tax-withholding dispositions, Sukhatme directly owned 18,677,617 Common Shares.
Roivant Sciences director Meghan Fitzgerald exercised stock options for 70,000 Common Shares at an exercise price of $8.80 per share and immediately sold the same 70,000 shares in an open-market transaction. The sale had a weighted average price of $27.45 per share, with individual trades executed between $27.32 and $27.80. Following these transactions, Fitzgerald directly holds 42,963 Common Shares, and the exercised option award is now fully vested and exhausted.
Roivant Sciences Ltd. CFO Richard Pulik reported a tax-related share disposition tied to restricted stock units (RSUs). The company net-settled 1,546 Common Shares on March 20, 2026 to satisfy applicable tax withholding obligations upon RSU vesting, rather than through an open-market sale.
After this tax-withholding transaction, Pulik directly holds 236,867 Common Shares. This type of F-code transaction is a routine administrative step associated with equity-based compensation, reflecting shares withheld for taxes instead of cash payment.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported a tax-related share disposition tied to restricted stock units. On the vesting and settlement of previously granted RSUs, the issuer net-settled 14,526 Common Shares at $27.70 per share to cover withholding obligations. After this non‑market transaction, Humes directly holds 97,729 Common Shares, indicating the event is compensation- and tax-driven rather than an open-market trade.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker exercised stock options for 200,000 Common Shares at an exercise price of $3.85 per share and on the same day sold 200,000 Common Shares in open-market transactions at a weighted average price of $28.24 per share.
Following these transactions, Venker directly owned 1,647,546 Common Shares. The sale price reflects multiple trades within a range from $28.04 to $28.45, as disclosed in the filing footnotes.
Roivant Sciences Ltd. director Melissa B. Epperly reported an open-market sale of 41,861 common shares on March 16, 2026 at a weighted average price of $28.68 per share. The shares were sold in multiple trades priced between $28.50 and $28.84. After this transaction, she directly holds 15,804 common shares of Roivant Sciences.
Roivant Sciences Ltd. reported that CFO Richard Pulik had 1,000 common shares withheld at a price of $27.15 per share to cover tax obligations from the vesting of previously granted RSUs. After this tax-withholding disposition, he directly holds 238,413 common shares.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported a Form 4 showing a tax-related share disposition. On this date, 7,051 common shares were withheld and net-settled by the company to satisfy tax withholding obligations arising from the vesting of previously granted RSUs. After this tax-withholding disposition, Venker directly owned 1,647,546 common shares.
Roivant Sciences Ltd. President and Vant Chair Frank Torti reported a series of stock option exercises and related share sales. Between February 19 and 23, he exercised options to acquire a total of 3,000,000 Common Shares at an exercise price of $3.85 per share and then sold the same number of shares in open-market transactions.
The sales covered 1,400,000, 1,012,610, and 587,390 Common Shares at weighted average prices of $27.42, $27.15, and $27.51 per share, respectively, with individual trades occurring between $26.70 and $27.80. After these transactions, Torti directly owned 13,736,547 Common Shares and held 3,026,184 stock options.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported exercising stock options and selling shares on the same day. He exercised options for 200,000 Common Shares at an exercise price of $3.85 per share, then sold 200,000 Common Shares in open-market transactions at a weighted average price of $26.49 per share, with individual sale prices ranging from $26.35 to $26.69. Following these transactions, he directly owned 1,654,597 Common Shares and held 5,044,834 stock options.
Roivant Sciences director-associated entity reports share sales. An investment entity, QVT Financial Investment Cayman Ltd., which is associated with director Keith S. Manchester, executed several indirect open-market sales of Roivant Sciences common shares between February 11 and 13, 2026.
Transactions included sales of 425,000 shares at $26.67, 150,000 shares at $26.72, 275,000 shares at $26.76, 150,784 shares at $26.49, and 225,000 shares at $26.50. Following these trades, QVT Financial Investment Cayman Ltd. is reported as indirectly holding 15,127,329 common shares.
The filing notes that Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
Roivant Sciences Ltd. reported insider share sales linked to director Daniel Allen Gold. QVT Financial Investment Cayman Ltd., where Gold is one of three directors, executed a series of open-market sales of Roivant common shares on February 11–13, 2026 at prices between $26.49 and $26.76 per share.
Individual transactions ranged from 150,000 to 425,000 common shares, with the last reported sale at $26.50 per share. Following the final transaction, 15,127,329 common shares were indirectly held by QVT Financial Investment Cayman Ltd. Gold shares voting and investment control over these shares and disclaims beneficial ownership beyond his pecuniary interest.
QVT Financial LP, acting as a director by deputization of Roivant Sciences Ltd., reported a series of indirect open‑market sales of Roivant common shares held by QVT Financial Investment Cayman Ltd. on February 11–13, 2026. The transactions included sales of 425,000, 150,000, 275,000, 150,784 and 225,000 common shares at prices between $26.49 and $26.76 per share. Following these trades, QVT Financial Investment Cayman Ltd. held 15,127,329 Roivant common shares indirectly for QVT Financial LP, while footnotes state that QVT Financial LP may be deemed to beneficially own 25,161,237 common shares across several related entities.
Sukhatme Mayukh reported multiple insider transaction types in a Form 4 filing for ROIV. The filing lists transactions totaling 1,954,674 shares at a weighted average price of $19.58 per share. Following the reported transactions, holdings were 18,836,547 shares.
Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. On January 20, 2026, he received an award of 609 Common Shares under the company’s Non-Employee Director Compensation Plan, which were fully vested on the grant date and recorded at $0 per share as a stock grant. On the same date, 122 Common Shares were withheld and forfeited at $22.98 per share through a net settlement to cover tax withholding obligations tied to the vesting of previously granted shares. After these transactions, he directly owned 109,030 Common Shares.
Roivant Sciences director Oren Ilan reported stock-based compensation and related tax withholding transactions. On 01/20/2026, he received 1,164 Common Shares at $0 under Roivant Sciences Ltd.'s Non-Employee Director Compensation Plan, and this award was fully vested on the grant date. On the same day, 124 Common Shares were withheld and settled at $22.98 per share to cover applicable tax obligations tied to the vesting and settlement of previously granted shares. After these transactions, he directly owned 119,428 Common Shares.
Roivant Sciences Ltd. director Melissa Epperly reported routine equity compensation activity. On January 20, 2026, she received an award of 815 Common Shares under Roivant’s Non-Employee Director Compensation Plan, which the footnotes state was fully vested on the grant date and issued at $0 per share as part of her director compensation.
On the same day, 54 Common Shares were withheld in a transaction coded “F” at $22.98 per share to cover tax withholding obligations tied to the vesting and settlement of previously granted shares. After these transactions, Epperly directly beneficially owned 57,665 Common Shares of Roivant Sciences.
Roivant Sciences Ltd. executive Eric Venker, President & Immunovant CEO, reported an option exercise and share sale. On January 12, 2026, he exercised stock options covering 200,000 Common Shares at an exercise price of $3.85 per share. That same day, he sold 200,000 Common Shares at a weighted average price of $21.92 per share, with individual sale prices ranging from $21.59 to $22.20.
After these transactions, Venker directly held 1,654,597 Common Shares and 5,244,834 stock options representing rights to buy additional Common Shares. The option award originally began vesting on April 20, 2022, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, subject to his continued service.
Roivant Sciences Ltd. director Dan Gold reported multiple sales of the company’s Common Shares made indirectly through QVT Financial Investment Cayman Ltd. On 12/16/2025, QVT FIC sold 275,000 Common Shares at a price of $22.93 per share and 642,282 Common Shares at $23.08 per share. On 12/17/2025, QVT FIC sold additional blocks of 432,718, 155,076, and 189,538 Common Shares at prices of $23.05, $23.02, and $23.17 per share, respectively.
Following these transactions, QVT FIC is reported to beneficially own 16,353,113 Roivant Common Shares, which are reported as indirectly owned by Gold through his role as one of three directors of QVT FIC. Gold disclaims beneficial ownership of these securities beyond his pecuniary interest.
Roivant Sciences Ltd. insider trading report: CEO and director Matthew Gline reported multiple transactions in Roivant common shares on 12/15/2025. He exercised stock options to buy 234,096 shares at $4.06 and a total of 3,636,563 shares at $12.68, then reported sales of 230,357, 566,116 and 943,527 shares at $21.68 per share. Additional share dispositions reflect “net settlement” of options to cover exercise prices. After these transactions, he reported beneficial ownership of 17,287,081 common shares held directly.
The filing notes that all options expiring in 2026 were exercised, eliminating that option position, and states that Gline has disgorged to Roivant the full amount of disgorgable profits from the sales as required by Section 16(b) of the Exchange Act.
Roivant Sciences director Vivek Ramaswamy reported large stock option exercises and related share sales in December 2025. On 12/11, 12/12 and 12/15, he exercised options at $12.68 per share to acquire 1,869,691, 4,672,724 and 832,453 common shares, respectively. On those same dates he sold 774,142, 1,975,858 and 353,745 shares at weighted average prices of $21.64, $21.96 and $22.05, and additional shares were disposed of through issuer net settlement to cover option exercise costs.
After these transactions, he beneficially owned 33,653,755 common shares directly and 13,357,857 shares indirectly through his spouse. The exercised options would have expired in March 2026 if not exercised and arise from awards that began vesting on December 27, 2019.
Immunovant, Inc. reported an insider transaction by a reporting person who is both a director and a 10% owner. On December 12, 2025, this filer purchased 16,666,666 shares of Immunovant common stock at $21 per share. Following the transaction, the filer directly beneficially owned 113,317,007 Immunovant shares. The filer is considered a director by deputization because senior executives of Roivant Sciences, Inc., a subsidiary of the reporting person, currently serve on Immunovant’s board on its behalf.
Roivant Sciences Ltd. officer Eric Venker, President & Immunovant CEO, reported equity transactions dated December 9, 2025. He exercised stock options to acquire 200,000 common shares at an exercise price of $3.85 per share, then sold 200,000 common shares at a weighted average price of $20.85 per share pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
After these transactions, he directly beneficially owned 1,497,908 common shares of Roivant Sciences. He also held 5,876,523 stock options exercisable into common stock at $3.85 per share, from a grant with a vesting commencement date of April 20, 2022 that vests 25% on the first anniversary and the remainder in 36 equal monthly installments, with an expiration date of April 19, 2032.
Roivant Sciences Ltd. (ROIV) reported an insider equity transaction by its Chief Financial Officer. On 11/20/2025, the CFO had 1,235 common shares withheld at a price of $20.27 per share. This was a "net settlement" of previously granted restricted stock units (RSUs) to cover tax withholding obligations when those RSUs vested and were settled.
After this tax-related share withholding, the CFO beneficially owns 388,273 common shares, held directly. The filing indicates this was an administrative equity compensation event, not an open-market purchase or sale.
Roivant Sciences Ltd. insider transaction: A Form 4 reports that officer Eric Venker, President & Immunovant CEO, had 7,051 common shares of Roivant Sciences Ltd. withheld on 11/20/2025 at a price of $20.27 per share. The filing explains this was a "net settlement" of previously granted restricted stock units (RSUs) by the company to cover applicable tax withholding when those RSUs vested and settled.
After this tax-related share withholding, Venker directly beneficially owns 1,497,908 common shares of Roivant Sciences Ltd. This type of transaction does not represent an open-market sale, but rather an administrative step tied to equity compensation vesting.
Roivant Sciences Ltd. (ROIV) director reported multiple indirect sales of common shares on 11/19/2025. The transactions were coded as open-market sales, with blocks of shares sold at prices between $20.16 and $20.25 per share through QVT Financial Investment Cayman Ltd.
Following these sales, the reporting person shows 18,047,727 Roivant common shares beneficially owned on an indirect basis through QVT Financial Investment Cayman Ltd. The filing notes that the individual is a shareholder of that entity but has no voting or investment control over it and expressly disclaims beneficial ownership of the reported shares beyond any pecuniary interest.
Roivant Sciences Ltd. (ROIV) director Dan Gold reported several open‑market sales of the company’s Common Shares on 11/19/2025. Indirectly through QVT Financial Investment Cayman Ltd., he sold 850,000 shares at $20.25, 150,000 shares at $20.20, 125,000 shares at $20.16, and 175,000 shares at $20.24, all coded as sales. Following these transactions, 18,047,727 Common Shares were beneficially owned indirectly, reported as held by QVT Financial Investment Cayman Ltd. The filing notes that Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership beyond his pecuniary interest.
Roivant Sciences Ltd. (ROIV) filed a Form 4 showing a significant shareholder-related sale of common shares. On 11/19/2025, an entity associated with QVT sold a total of 1,300,000 Roivant common shares in four open-market transactions at prices between $20.16 and $20.25 per share. After these sales, 18,047,727 common shares were reported as beneficially owned indirectly through QVT Financial Investment Cayman Ltd.
The explanation notes that QVT Financial LP and its related entities may be deemed to beneficially own 28,081,635 Roivant common shares in aggregate through several affiliated vehicles. QVT states that it disclaims beneficial ownership of these shares except to the extent of any pecuniary interest.
Roivant Sciences Ltd. director and more-than-10% owner Vivek Ramaswamy reported multiple open-market sales of the company’s common shares. On 11/13/2025 he sold 287,283 shares at a weighted average price of $20.81, on 11/14/2025 he sold 1,027,670 shares at a weighted average of $20.33, and on 11/17/2025 he sold 539,650 shares at a weighted average of $20.51. The prices reflect multiple individual trades within stated ranges for each day. After these transactions, he beneficially owned 33,653,756 common shares directly and 13,357,857 common shares indirectly through his spouse.
Roivant Sciences (ROIV): Officer Eric Venker reported an option exercise and same‑day sale. On 11/07/2025, he exercised 200,000 stock options at an exercise price of $3.85 per share (code M) and sold 200,000 common shares at a weighted average price of $20.22 (code S). Following these transactions, he reported 1,504,959 common shares beneficially owned directly and 6,076,523 derivative securities beneficially owned. The sales were made under a Rule 10b5‑1 trading plan adopted on March 28, 2025.
Venker is listed as President & Immunovant CEO. The options relate to an award with a vesting schedule beginning April 20, 2022, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continuous service.